Zymeworks Inc

Change company Symbol lookup

Select an option...

ZYME Zymeworks Inc

LIFW MSP Recovery Inc

ASNS Actelis Networks Inc

AHI Advanced Health Intelligence Ltd

OTLK Outlook Therapeutics Inc

PBHC Pathfinder Bancorp Inc (MARYLAND)

CMA Comerica Inc

IART Integra Lifesciences Holdings Corp

ARKW.SO ARK Next Generation Internet ETF

AGNC Agnc Investment Corp

Go

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. It is also advancing a pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas with an emphasis on developing ADC and multi-specific antibody therapeutics (MSAT) candidates. Its pipeline of preclinical product candidates includes two lead programs, ZW191 and ZW17.